MEDBOT-B (02252) surged over 6% in early trading, with gains moderating to 4.48% at the time of writing, trading at HK$21 with a turnover of HK$44.38 million. The catalyst for the rally stems from its recent inclusion in the newly launched HKEX Tech 100 Index on December 9, reflecting strong market recognition of the company’s technological innovation capabilities, leadership in biotech, and long-term growth potential.

Earlier in October, J.P. Morgan highlighted MEDBOT-B’s robust global order momentum, reporting over 170 cumulative surgical robot orders as of October 8—up from 150 at end-August. The bank revised its 2023 installation forecast upward from 84 to 105 units, citing faster overseas expansion and an assumption that orders could convert to revenue within a quarter. The upgrade also factors in improved product mix and an expected 1–1.5 percentage-point gross margin expansion.